Start here if you're new
what it is
Curis develops cancer drugs, led by emavusertib, an oral IRAK4 inhibitor that blocks a protein target in its trials.
how it gets paid
Last year Curis made $11M in revenue. Collaboration revenue was the main engine at $4.4M, or 40% of sales.
what just happened
Curis posted $8M of revenue in the latest quarter while EPS was -$2.19.
At a glance
C balance sheet — red flag territory — real financial stress
65/100 earnings predictability — reasonably predictable
-$6.88 fy2024 eps est
$11M fy2024 rev est
n/a operating margin
xvary composite: 28/100 — weak
What they do
Curis develops cancer drugs, led by emavusertib, an oral IRAK4 inhibitor that blocks a protein target in its trials.
You are not buying scale. You are buying focus. Curis has 33 employees and one lead drug story, so every trial readout matters more than a bigger sales team. Oral means swallowed pill, not IV drip. That matters because pills are easier for patients and clinics than hospital infusions. The quiet part is simple: one molecule can move the stock more than $11M of revenue can.
How they make money
$11M
annual revenue
Collaboration revenue
$4.4M
License revenue
$3.0M
Milestone revenue
$2.2M
Grant revenue
$1.1M
Other revenue
$0.3M
The products that matter
clinical-stage cancer drug
Emavusertib (CA-4948)
$13M market cap anchor
this is the asset the equity is really pricing. when a company is worth about $13M, one trial program can be the whole story.
primary value driver
legacy royalty stream
Erivedge Royalty
$11.7M trailing revenue
it generated the company’s $11.7M in trailing revenue. that keeps some cash coming in, but it does not solve the balance-sheet problem.
current revenue source
partnered and preclinical pipeline
Other Pipeline Assets
3 listed candidates
the company lists three drug candidates, but only one is in clinical development. that leaves you with very little near-term diversification if emavusertib disappoints.
limited backup
Key numbers
$11M
FY2024 revenue
That is tiny next to $22M of long-term debt, so the business is still financing itself more than selling itself.
$6.88
FY2024 EPS
You lost $6.88 per share in 2024, which means each dollar of equity bought a bigger hole.
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. For every $1 of sales, operating loss was about $4.08, so scale is not close yet.
$22M
long-term debt
Debt is about 1.7x the $13M market cap, so creditors sit above equity.
Financial health
C
strength
- balance sheet grade C — very weak — significant financial distress
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $22M (63% of capital)
C — balance sheet grade and long-term debt are flagged. this stock carries more risk than average.
Total return vs. market
Return history isn't available for CRIS right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Curis posted $8M of revenue in the latest quarter while EPS was -$2.19.
Revenue rose 161% vs. prior year, but the company still lost money. Trailing revenue was $11M, so the quarter did not fix the scale problem.
$8M
revenue
-$2.19
eps
n/a
n/a
the number that mattered
The number that mattered was $8M, because it shows how small the business still is.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is emavusertib failing to create enough value before Curis needs more capital.
med
single-asset clinical failure
The equity story is concentrated in one program. With a market cap around $13M and only one clinical asset carrying the case, a weak readout would not hurt the thesis — it would largely remove it.
A bad outcome would hit the part of the business investors actually care about.
med
liquidity pressure and dilution
A 0.74 current ratio means short-term obligations already matter. The January 2026 $80.8M private placement and the February 2026 process tied to about 107.71M shares say management is solving the same problem the market sees.
Even if the science holds up, your ownership can be diluted while the company buys time.
med
thin business diversification
Trailing revenue of $11.7M comes from a legacy royalty, not from a broad commercial engine. The company lists three drug candidates, but only one is in clinical development, so there is little near-term backup if the lead asset slips.
That leaves very few ways for the story to improve besides better emavusertib data.
A $13M market cap, $22M of debt, and a 0.74 current ratio tell you the same thing: this is a binary biotech wrapped inside a financing story.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
Q4 2025 earnings on March 19, 2026
You want the cash update more than the headline revenue number. After the January 2026 financing, runway commentary matters most.
metric
current ratio moving above 1.0
0.74 means Curis does not fully cover short-term bills with short-term assets. If that moves above 1.0, the liquidity story gets less fragile.
risk
whether dilution slows after the $80.8M raise
The February 2026 process tied to about 107.71M shares suggests financing pressure may not be finished. You want that pressure to ease, not compound.
trend
emavusertib becoming more important than the royalty
Right now the legacy royalty pays the bills while the pipeline drives the speculation. The stock improves only if clinical progress starts to outweigh that mismatch.
Analyst rankings
earnings predictability
65 / 100
The royalty stream makes results somewhat more readable than most pre-revenue biotechs. In human-speak, analysts can model the current revenue line better than they can model the science.
risk profile
5 / 100 stability context
This is not an official analyst rating, but it matters. A price stability score of 5 / 100 tells you the market treats CRIS like a binary event stock.
source: institutional data
Institutional activity
institutional ownership data for CRIS is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive